Sandra Burchett, MD, MSc
Senior Associate Physician in Pediatrics, Division of Infectious Diseases; Director, Children's Hospital AIDS Program (CHAP)
Associate Professor of Pediatrics, Harvard Medical School
Image
Sandra Burchett, MD, MSc
Senior Associate Physician in Pediatrics, Division of Infectious Diseases; Director, Children's Hospital AIDS Program (CHAP)
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Graduate School
University of Arkansas
1978
Little Rock
AR
Medical School
University of Arkansas College of Medicine
1983
Little Rock
AR
Internship
Arkansas Children's Hospital
1984
Little Rock
AR
Residency
Pediatrics
Arkansas Children's Hospital
1985
Little Rock
AR
Fellowship
Pediatric Infectious Diseases
Children's Hospital and Medical Center
1989
Seattle
WA
Certifications
American Board of Pediatrics (Infectious Diseases)
Publications
A Digital Platform to Support HIV Case Management for Youth and Young Adults: Mixed Methods Feasibility Study. View Abstract
Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center. View Abstract
Immunologic and Virologic Factors Associated With Hospitalization in Human Immunodeficiency Virus-Exposed, Uninfected Infants in the United States. View Abstract
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV. View Abstract
Rates of Hospitalization and Infection-Related Hospitalization Among Human Immunodeficiency Virus (HIV)-Exposed Uninfected Children Compared to HIV-Unexposed Uninfected Children in the United States, 2007-2016. View Abstract
Neurodevelopment of HIV-Exposed Uninfected Infants Born to Women With Perinatally Acquired HIV in the United States. View Abstract
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. View Abstract
Immune imbalance and activation are associated with lower lung function in youth with perinatally acquired HIV. View Abstract
Birth Prevalence of Congenital Cytomegalovirus Infection in HIV-Exposed Uninfected Children in the Era of Combination Antiretroviral Therapy. View Abstract
Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection. View Abstract
Immunologic reconstitution following hematopoietic stem cell transplantation despite lymph node paucity in NF-?B-inducing kinase deficiency. View Abstract
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. View Abstract
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. View Abstract
Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. View Abstract
Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab. View Abstract
Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth. View Abstract
Lymphocyte subsets in HIV-exposed uninfected infants and HIV-unexposed uninfected infants. View Abstract
Case Report of a Child after Hematopoietic Cell Transplantation with Acute Aspergillus Tracheobronchitis as a Cause for Respiratory Failure. View Abstract
Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy. View Abstract
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. View Abstract
Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. View Abstract
Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy. View Abstract
Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. View Abstract
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. View Abstract
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. View Abstract
Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. View Abstract
Pharmacokinetics of tenofovir during pregnancy and postpartum. View Abstract
Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. View Abstract
Raltegravir pharmacokinetics during pregnancy. View Abstract
Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. View Abstract
Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. View Abstract
Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review. View Abstract
Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. View Abstract
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. View Abstract
The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. View Abstract
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. View Abstract
T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children. View Abstract
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. View Abstract
Effect of pregnancy on emtricitabine pharmacokinetics. View Abstract
Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. View Abstract
CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. View Abstract
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. View Abstract
Atazanavir pharmacokinetics with and without tenofovir during pregnancy. View Abstract
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. View Abstract
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. View Abstract
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. View Abstract
Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. View Abstract
Lopinavir protein binding in HIV-1-infected pregnant women. View Abstract
CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy.
View Abstract
Case 15-2009: a man with coma after cardiac arrest. View Abstract
Immune response to influenza vaccine in children with inflammatory bowel disease. View Abstract
Lopinavir exposure with an increased dose during pregnancy. View Abstract
Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. View Abstract
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. View Abstract
High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum View Abstract
CYP2C19 Genetic Variants Affect Nelfinavir and M8 Pharmacokinetics and Virologic Response in HIV-1 Infected Children Receiving HAART View Abstract
Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. View Abstract
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. View Abstract
Viral Infections View Abstract
International perspectives, progress, and future challenges of paediatric HIV infection. View Abstract
Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third Trimester of Pregnancy and Post-partum View Abstract
Tenofovir Pharmacokinetics during Pregnancy, at Delivery and Postpartum View Abstract
Reduced lopinavir exposure during pregnancy. View Abstract
Impact of pregnancy on abacavir pharmacokinetics. View Abstract
Lopinavir exposure with a higher dose during the 3rd trimester of pregnancy View Abstract
Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response View Abstract
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. View Abstract
Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. View Abstract
Pediatric Human Immunodeficiency Virus Infection View Abstract
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: pediatric AIDS clinical trials group protocol 332 View Abstract
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. View Abstract
Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026 View Abstract
Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. View Abstract
Mother-to child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 US women (PACTG 367) View Abstract
Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy View Abstract
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. View Abstract
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. View Abstract
HIV Infection in Infants, Children, and Adolescents View Abstract
Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. View Abstract
HIV infection in infants, children, and adolescents. View Abstract
Congenital Infections View Abstract
Viral Infections View Abstract
Robust Gag-specific T-helper Response Associated with Viral Control in Pediatric HIV Infection View Abstract
Pharmakokinetics and Safety of d4T and 3TC in HIV-infected Pregnant Women and Their Infants (PACTG 332) View Abstract
HIV Infection in Infants, Children, and Adolescents View Abstract
Perinatal Infections View Abstract
Mother-to-Child HIV Transmission Rates According to Antiretroviral Therapy, Mode of Delivery and Viral Load (PACTG 367) View Abstract
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection View Abstract
Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. View Abstract
Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. View Abstract
Evolution and transmission of stable CTL escape mutations in HIV infection. View Abstract
The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. View Abstract
HIV-1 Reverse Transcriptase M184V/I Improves the Rate of Suppression of Viral Replication by Salvage Therapy View Abstract
Virologic and Immunologic Responses in Children with Advanced HIV Disease on a New HAART Regimen (PACTG 366) View Abstract
HIV-Infected Children on HAART Reconstitute Tetanus-Specific T Cell Responses without Booster Vaccination View Abstract
The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children View Abstract
The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children View Abstract
Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management View Abstract
Human immunodeficiency virus type 1 (HIV-1) gp 120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine View Abstract
Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. View Abstract
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. View Abstract
Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. View Abstract
Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. View Abstract
Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. View Abstract
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group. View Abstract
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. View Abstract
Viral load reduction (VLR) in children with advanced HIV disease treated with 4-drug antiretroviral treatment (ART) regimens including NRTIs, Nevirapine (NVP), Nelfinavir (NFV), and/or Ritonavir (RTV):PACTG 366 View Abstract
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). View Abstract
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children View Abstract
Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The pediatric AIDS clinical trials group View Abstract
Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts View Abstract
HIV vertical transmission rates according to antiretro-viral therapy and viral load during pregnancy among 347 mother-child pairs 1998-99 (PACTG 367) View Abstract
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type-1 infected children (Pediatric AIDS clinical trials group protocol 273) View Abstract
Antepartum antiretroviral therapy and viral load in 464 HIV-infected women in 1998-1999 (PACTG 367) View Abstract
Identification of dominant optimal HLA-B6-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay View Abstract
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The pediatrics AIDS clinical trials group View Abstract
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. View Abstract
Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. View Abstract
Preliminary toxicity and tolerability of 4-drug antiretroviral (ARV) therapy with NRTIs, Nevirapine (NVP), Nelfinavir (NFV) and Ritonavir (RTN) in ARV-experienced children with advanced HIV disease View Abstract
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants View Abstract
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. View Abstract
Diagnosis of HIV Infection and Markers of Disease Progression in Infants View Abstract
Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. View Abstract
Viral Infections View Abstract
Congenital Infections View Abstract
Combinations of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) can reduce CSF HIV-1 viral load in pediatric patients with advanced HIV disease View Abstract
Maternal human immunodeficiency virus (HIV) RNA level correlates with the risk but does not predict the timing of perinatal transmission View Abstract
Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. View Abstract
Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. View Abstract
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. View Abstract
Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. View Abstract
Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents. View Abstract
Virologic activity of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245) View Abstract
Effect of pregnancy and zidovudine therapy on viral load in HIV-I-infected women View Abstract
Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children View Abstract
Analysis of the maternal components of the AIDS clinical trials group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1 View Abstract
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. View Abstract
Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. View Abstract
Secretory phospholipase A2 levels in rat small bowel. View Abstract
Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. View Abstract
Lack of correlation between CMV infection and central neurological compromise in HIV-infected children View Abstract
Functional characterization of autoreactive T-cells in acute disseminated encephalomyelitis View Abstract
Interferon gamma and IL-6 secretion of peripheral blood mononuclear cells is significantly increased in infants with perinatal HIV infection View Abstract
Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial View Abstract
Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral apthhous ulcers View Abstract
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National institute of allergy and infectious diseases and infectious diseases collaborative antiviral study group View Abstract
Early Toxicity Experience in Combination Therapy of Advanced Pediatric HIV Disease View Abstract
Clearance of HIV--lessons from newborns. View Abstract
Clearance of HIV: Lessons from newborns View Abstract
Correlates of CNS Disease Progression in Children Vertically-Infected with HIV View Abstract
Defining Pediatric "Rapid HIV Progressors" by Plasma Viremia and Sequential Western Blot View Abstract
Protective Immunity View Abstract
Maternal hepatitis C (HCV) infection is not a cofactor for enhanced rate of vertical transmission of HIV-I View Abstract
The Placental Barrier to HIV-1 Transmission View Abstract
Plasma viral load in symptom-free women and vertical transmission of HIV-1. View Abstract
Maternal hepatitis C (HCV) infection does not enhance the rate of vertical transmission of HIV View Abstract
Correlates of vertical transmission of human immunodeficiency virus (HIV) View Abstract
Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. View Abstract
Early diagnosis of HIV in infants born to seropositive women View Abstract
Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. View Abstract
The role of the placental macrophage in prevention of vertical transmission of HIV View Abstract
Clostridium septicum infections in children View Abstract
Culture: An early diagnostic tool in infants born to HIV infected women View Abstract
Diminished ability of fetal and neonatal macrophages to support proliferative human immunodeficiency infection View Abstract
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. View Abstract
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. View Abstract
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. View Abstract
Pharmacokinetic disposition of zidovudine during pregnancy. View Abstract
Comparative susceptibility of neonatal lymphocytes and monocytes to HIV infection View Abstract
Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. View Abstract
HIV infection in pregnancy and infancy in AIDS. Diagnosis and treatment View Abstract
Modulation of in vitro monocyte cytokine responses during infection with Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1 View Abstract
Association between plasma human immunodeficiency virus type-1 (HIV) viremia and clinical class of pediatric HIV infection View Abstract
The use of antiviral drugs in pregnancy for herpes simplex virus infections View Abstract
Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells. View Abstract
Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. View Abstract
Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. View Abstract
Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes View Abstract
Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock View Abstract
Expression of HLA class II antigens and secretion of interleukin-1 by monocytes and macrophages from adults and neonates. View Abstract
The role of computerized tomographic scan in the management of Gradenigo's syndrome: a case report. View Abstract
Immunologic profile of growth hormone deficient children before and during growth hormone replacement View Abstract
Locations